Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subconjunctival Triamcinolone vs Botulinum Toxin for Upper Lid Retraction in Thyroid-associated Ophthalmopathy
TCTR20260701006Phase 4Completed
- Sponsor
- Vajira Hospital
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of triamcinolone, neuronox in Graves Orbitopathy (GO), Upper eyelid retraction, sponsored by Vajira Hospital. Started Jul 2025; status: completed.
02
Drugs
triamcinoloneneuronox
03
Conditions
Graves Orbitopathy (GO)Upper eyelid retraction
Beyond the preview
Go deeper on TCTR20260701006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260701006.